https://www.selleckchem.com/pr....oducts/apoptozole.ht
Building on our previously-reported novel tricyclic topoisomerase inhibitors (NTTIs), we disclose the discovery of REDX07965, which has an MIC90 of 0.5 μg mL-1 against Staphylococcus aureus, favourable in vitro pharmacokinetic properties, selectivity versus human topoisomerase II and an acceptable toxicity profile. The results herein validate a rational design approach to address the urgent unmet medical need for novel antibiotics.The alarming reduction in drug effectiveness against bacterial infections has created an urgent need for
Mi piace
Commento
Condividi
